UNSPSC 51401525: Flumazenil

This classification denotes a neuroprotective agent with the molecular formula C15H14FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40P7XK9392, chemically known as 4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester but generally known as flumazenil, which bears US NIH Compound Identifier 3373. European Medicines Agency schedules Flumazenil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07693MIG.

UNSPSC 51401525 Flumazenil (Commodity) does not reflect the actual scope of recent state and local procurement activity tagged under this code. The code nominally describes a specific benzodiazepine antagonist pharmaceutical, but the posted opportunities show state and local governments buying naloxone (an opioid antagonist), generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, and information-gathering on direct-to-manufacturer prescription programs—none of which are flumazenil. The mismatch suggests either a tagging error in the source data or a code classification that does not align with current procurement practice. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government facilities across participating jurisdictions including Oregon). The code shows little relevant recent activity under its stated pharmaceutical scope.

The geographic spread covers Florida, Texas, and the Upper Midwest through Minnesota's cooperative purchasing vehicle. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding with quarterly deliveries to Sanford, Florida; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements; and Minnesota Multistate Cooperative Purchasing Alliance's S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic pharmaceuticals and OTC products distributed through three authorized wholesalers with contract awards effective July 1, 2026. None of these solicitations target flumazenil specifically, reinforcing the disconnect between the code's nominal scope and procurement activity being recorded under it.